Quality of Vision After Implantation of EDOF Implants Versus Monofocal Implants in Patients Who Underwent Epiretinal Membrane and Cataract Surgery

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAlmaviva Sante

About this trial

Phacoexistence, the first surgical procedure performed in France, naturally raises the question of lens replacement. In recent years, the choice of intraocular lenses has expanded considerably. The term EDOF (Extended Depth of Focus) refers to intraocular lenses offering an extended depth of field to improve vision at different distances, while reducing the visual aberrations associated with traditional multifocal lenses.

However, they still generate some optical aberrations that could therefore limit the quality of vision for patients with retinal damage.

With the development and acceleration of cataractogenic processes observed after vitrectomy, the use of combined phaco-vitrectomy surgery has become increasingly common, particularly among patients over 60 years of age. This integrated approach allows for the simultaneous treatment of cataracts and vitreoretinal pathologies, thus reducing the need for subsequent cataract surgery, which frequently develops after vitrectomy. In addition to optimizing the patient care pathway, this technique offers clinical advantages, such as faster visual recovery and fewer complications associated with multiple surgeries. Phacovitrectomy is therefore emerging as a practical and effective solution for managing elderly patients requiring vitreoretinal surgery.

Therefore, in the specific context of macular surgery, often considered less suitable for the use of premium implants, EDOF (Extended Depth of Focus) implants raise some questions. The available data on their performance and tolerability in this specific context remain limited, making their use still poorly defined in these complex clinical situations, except in certain medical macular pathologies.\<sup\>4\</sup\> This study aims to evaluate, within the context of macular surgery, the relevance and potential role of EDOF (Extended Depth of Focus) implants in order to improve the management of these patients.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Male or female over 18 years of age

Epiretinal membrane with surgical indication

Indication for cataract surgery with intraocular lens implantation

Epiretinal membranes with near visual acuity ≥ P4

Disqualifiers

Associated ocular pathologies (advanced glaucoma, exudative AMD).

Central macular thickness > 450 microns

Epiretinal membranes with near visual acuity < P4

Previous macular surgery

Trial design

Design model

Parallel

Treatments tested in this trial

  • Questionnaires

    Other intervention

    NEI-VFQ (National Eye Institute Visual Function Questionnaire) 25 before the surgery, 3 months after and 6 months after the surgery.

  • Intermediate visual acuity

    Other intervention

    ETDRS (Early Treatment Diabetic Retinopathy Study) scale before the surgery and 1 month, 3 months and 6 months after the surgery

  • Optical coherence tomography

    Procedure/Surgery

    1 month, 3 months and 6 months after surgery

  • cataract surgery with intraocular lens implantation

    Procedure/Surgery

    Two different cataract surgeries : TECNIS monofocal versus PureSee EDOF (extended depth of focus)

Treatment groups

100 Participants
are divided into 2 treatment groups
Group A: Implants EDOFExperimental treatment 4 interventions
Group B: Monofocal implantsActive comparator 4 interventions

Trial outcomes

Primary outcomes

1

Distance visual acuity (4 m)

Distance visual acuity (4 m) using the ETDRS (Early Treatment Diabetic Retinopathy Study) scale at 3 months. This involves asking the patient, positioned 4 meters away, to read a chart made up of 5 letters per line, with the size gradually decreasing from top to bottom. The score is determined by counting the number of letters read correctly (each letter is worth 1 point). The maximum score is 100 to 110 letters depending on the version.

Time frame
3 months

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: